{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:32:49Z","timestamp":1771464769413,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.bbrc.2012.02.089","type":"journal-article","created":{"date-parts":[[2012,2,24]],"date-time":"2012-02-24T13:16:36Z","timestamp":1330089396000},"page":"584-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation"],"prefix":"10.1016","volume":"419","author":[{"given":"Yasuyuki","family":"Morikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2012.02.089_b0005","first-page":"258","article-title":"Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy","volume":"5","author":"Figg","year":"1997","journal-title":"Cancer Practice"},{"key":"10.1016\/j.bbrc.2012.02.089_b0010","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plusprednisone or mitoxantrone plus prednisone for advancedprostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2012.02.089_b0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/tcr.1008","article-title":"Chemistry and chemical biology of taxaneanticancer agents","volume":"1","author":"Miller","year":"2001","journal-title":"Chem. Rec."},{"key":"10.1016\/j.bbrc.2012.02.089_b0020","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1515\/CCLM.2002.161","article-title":"Overcoming multidrugresistance in taxane chemotherapy","volume":"40","author":"Geney","year":"2002","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.bbrc.2012.02.089_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1464-410X.2005.05946.x","article-title":"Therapeutic options in androgen-independent prostate cancer building on docetaxel","volume":"96","author":"Petrylak","year":"2005","journal-title":"BJU Int."},{"key":"10.1016\/j.bbrc.2012.02.089_b0030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ctrv.2006.01.004","article-title":"Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination","volume":"32","author":"Bergstralh","year":"2006","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bbrc.2012.02.089_b0035","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jnci\/85.6.478","article-title":"Restoration of Taxolsensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ280-446","volume":"85","author":"Jachez","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbrc.2012.02.089_b0040","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.1999.17.3.1061","article-title":"Sikic BI: mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death","volume":"17","author":"Dumontet","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2012.02.089_b0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1535-6108(02)00084-3","article-title":"Altieri DC:Ap34(cdc2) survival checkpoint in cancer","volume":"2","author":"O\u2019Connor","year":"2002","journal-title":"Cancer Cell."},{"key":"10.1016\/j.bbrc.2012.02.089_b0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","article-title":"The Akt-mTOR tango and its relevance to cancer","volume":"8","author":"Hay","year":"2005","journal-title":"Cancer Cell."},{"key":"10.1016\/j.bbrc.2012.02.089_b0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phoshoatidylinositol 3-kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2012.02.089_b0060","unstructured":"Qing-jun Liu, Xiu-hong Xu, Dong-hao Shang, et al., Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel. Chin. Med. J. 123 (2010) 356\u2013360."},{"key":"10.1016\/j.bbrc.2012.02.089_b0065","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.juro.2010.12.005","article-title":"Survivinis associated with cell proliferation and has a role in1a, 2,5-dihydroxyvitamin d3 induced cell growth inhibition in prostate cancer","volume":"185","author":"Koike","year":"2011","journal-title":"J. Urol."},{"key":"10.1016\/j.bbrc.2012.02.089_b0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.trim.2006.12.003","article-title":"Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro","volume":"17","author":"Zhang","year":"2007","journal-title":"Trans. Immunol."},{"key":"10.1016\/j.bbrc.2012.02.089_b0075","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3816\/CGC.2007.n.018","article-title":"Metastatic renal cell carcinoma role of mammalian target of rapamycin inhibitors","volume":"5","author":"Bukowski","year":"2007","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.bbrc.2012.02.089_b0080","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3816\/CGC.2008.n.015","article-title":"Pilot study of rapamycin in patients with hormone-refractory prostate cancer","volume":"6","author":"Amato","year":"2008","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.bbrc.2012.02.089_b0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2006.11.008","article-title":"Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer","volume":"251","author":"Nozawa","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2012.02.089_b0090","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0898-6568(01)00271-6","article-title":"The protein kinase B\/Akt signalling pathway in human malignancy","volume":"14","author":"Nicholson","year":"2002","journal-title":"Cell Signal"},{"key":"10.1016\/j.bbrc.2012.02.089_b0095","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1158\/1078-0432.CCR-08-3007","article-title":"Concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts","volume":"15","author":"Fung","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2012.02.089_b0100","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0b013e318155a439","article-title":"A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)","volume":"2","author":"Pandya","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbrc.2012.02.089_b0105","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2012.02.089_b0110","doi-asserted-by":"crossref","unstructured":"Peng Zhaoa, Qiao Mengb, Ling-Zhi Liu, Regulation of survivin by PI3K\/Akt\/p70S6K1 pathway. Biochem. Biophys. Res. Commun. 395 (2010) 219\u2013224.","DOI":"10.1016\/j.bbrc.2010.03.165"},{"key":"10.1016\/j.bbrc.2012.02.089_b0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0304-3835(02)00190-8","article-title":"Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma","volume":"184","author":"Takai","year":"2002","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2012.02.089_b0120","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/gut.46.5.645","article-title":"Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma","volume":"46","author":"Sarela","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.bbrc.2012.02.089_b0125","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1200\/JCO.1999.17.7.2100","article-title":"A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small cell lung cancers","volume":"17","author":"Monz\u00f3","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2012.02.089_b0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5858\/2004-128-39-SABEIP","article-title":"Survivinand Bcl-2 expression in prostatic adenocarcinomas","volume":"128","author":"Kaur","year":"2004","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.bbrc.2012.02.089_b0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pros.20232","article-title":"Adenoviral infection of survivin antisense sensitizes prostate cancer to etoposide in vivo","volume":"65","author":"Hayashi","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.bbrc.2012.02.089_b0140","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1471-4914(01)02243-2","article-title":"The molecular basis and potential role of surviving in cancer diagnosis and therapy","volume":"7","author":"Altieri","year":"2001","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbrc.2012.02.089_b0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/jcp.10327","article-title":"Survivin study: what is the next wave?","volume":"197","author":"Li","year":"2003","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.bbrc.2012.02.089_b0170","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.onc.1208490","article-title":"Survivin mediates resistance to antiandrogen therapy inprostate cancer","volume":"24","author":"Zhang","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2012.02.089_b0155","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.urology.2007.12.064","article-title":"Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer","volume":"72","author":"Koike","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.bbrc.2012.02.089_b0160","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.20039","article-title":"Survivin expression is associated with features of biologically aggressive prostate carcinoma","volume":"100","author":"Shariat","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2012.02.089_b0165","doi-asserted-by":"crossref","unstructured":"Huiyan Niu, Jiahe Wang, Hui Li, et al., Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin inlung cancer cells. J. Exp. Clin. Cancer Res. 30 (2011) 28.","DOI":"10.1186\/1756-9966-30-28"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X12003397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X12003397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T10:58:23Z","timestamp":1757761103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X12003397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0006291X12003397"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2012.02.089","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2012.02.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}